Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L18a pseudogene 17 (RPL18AP17) is a processed pseudogene in the human genome located on chromosome 13q21.33[4][6]. It derives its name from sequence similarity to the functional ribosomal protein L18a gene (RPL18A), which encodes a component of the 60S ribosomal subunit—a protein involved in cytoplasmic ribosomal structure and function[5][7][9]. However, as a pseudogene, RPL18AP17 does not produce a functional protein nor participate in ribosomal assembly, protein synthesis, or known biological processes[1][2][4][6][8]. There are many such pseudogenes in the human genome, originating as remnants from gene duplication or retrotransposition events but lacking the capacity for normal expression or function. RPL18AP17 has no known implications in human disease, drug targeting, or biomarker utility. If you require information on the functional ribosomal protein L18a (RPL18A), this is a distinct, protein-coding gene with documented biological functions in the ribosome, implications in viral biology, and minimal disease associations[5][7][9]. RPL18AP17 itself is not a legitimate therapeutic target or biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L18a pseudogene 17 (RPL18AP17).